Company news

Noxopharm Ltd. news in 2018

Noxopharm Ltd.'s news releases, calls and decks from 2018, newest first.

View company

NOX Receives $3.26M Federal Govt R&D Rebate

December 20, 2018

DARRT-1 study advancing on basis of positive clinical data

December 10, 2018

NOX announces Positive Data from CEP-1 Study of Veyonda

November 28, 2018

NOX to Present Clinical Data at COSA Annual Meeting

November 12, 2018

Appendix 4C - quarterly

October 25, 2018

Change of Registry Address: Automic P/L - Sydney Office

September 28, 2018

NOX Subsidiary Announces Important Drug Discovery

September 24, 2018

NOX to support expanded LuPIN study

September 4, 2018

Nyrada-Key progress with cholesterol-lowering drug candidate

August 26, 2018

VEYONDA - Registered Trade Mark for NOX66

August 20, 2018

Release of DARRT-1 Preliminary Safety Data

July 8, 2018

Pre-Clinical data confirms Radio-Enhancing potential

July 4, 2018

End-of-Study Clinical Data shows benefit of NOX66

June 5, 2018

NOX to present at American Society of Clinical Oncology

May 21, 2018

NOX CEO interview on near complete NOX66 chemotherapy trial

May 3, 2018

NOX CEO interview on Radiotherapy Clinical Programs

April 27, 2018

St Vincents Hospital study passes first milestone

April 16, 2018

DARRT-1 Clinical Study commences

April 5, 2018

NOX raises $10.8 M to advance clinical program

March 22, 2018

Evidence of Abscopal Responses in Patients

March 20, 2018

NOX Reports NOX66 Clinical Data

March 5, 2018

Appendix 4D and Half Year Accounts

February 22, 2018

NOX closes $4m capital raising for US subsidiary Nyrada Inc

February 15, 2018

NOX receives FY17 R&D Tax Rebate

January 17, 2018

Decks in 2018